One-third of Women Treated for Breast Cancer Are Not Getting Appropriate Breast Imaging Follow-up Exam, New Study Finds

Thursday, October 20, 2016 Cancer News J E 4
Underuse of surveillance breast imaging linked to sociodemographic and clinical factors according to new National Cancer Data Base analysis

WASHINGTON, Oct. 19, 2016 /PRNewswire-USNewswire/ -- An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.

While previous studies on Medicare patients suggest that surveillance imaging is underutilized, the use of mammography in a broad range of women diagnosed with breast cancer is unknown, as is the role of surveillance magnetic resonance imaging (MRI).

For this study, Caprice C. Greenberg, MD, MPH, FACS, of the University of Wisconsin School of Medicine and Public Health, and colleagues assessed the receipt of surveillance breast MRI and mammography in 9,622 women who underwent a surgical procedure to treat Stage II and III breast cancer from 2006 through 2007 with data collected from the National Cancer Database (NCDB). The NCDB is jointly sponsored by the American College of Surgeons and the American Cancer Society. Dr. Greenberg is professor of surgery and Morgridge Distinguished Chair in Health Services Research, of the University of Wisconsin School of Medicine and Public Health, Madison.

The researchers assessed imaging, cancer recurrence, new cancer, and death from the time of treatment and for five years after diagnosis. Next, they collected additional data on the reason for imaging (diagnostic evaluation of a new sign or symptom or surveillance imaging in the absence of signs and symptoms). Fifty percent of the study population was under age 60.

"Most of what we know about breast imaging comes from small studies or from Medicare data, a population that is 65 years old and older," said Dr. Greenberg, who is also the Director of the Wisconsin Surgical Outcomes Research Program (WiSOR). "This study is the first to look at a large, multi-institutional population of patients across all age groups."

According to study results, annual receipt of surveillance breast imaging declined 8 percent from the first year (66 percent) to the fourth year (58 percent). Study findings also indicate that among women who received surveillance imaging, only about 10 percent received breast MRIs.

"The most striking finding is that over 30 percent of women don't even get surveillance breast imaging in the first place," Dr. Greenberg said. "For some reason, we are not plugging them into follow-up surveillance from the outset. We also see that there are some disparities in the use of mammograms after the treatment of breast cancer."

The study shows that factors associated with not receiving breast imaging include younger age, black race, public or no insurance, worse health, more advanced cancers, receipt of excision alone or mastectomy (versus lumpectomy with radiation), and lack of systemic therapy.

"The critical story here is that if women start off their follow-up care receiving guideline-recommended imaging, they're likely to continue to receive that imaging over time. Women who don't receive imaging in that first follow-up year are not likely to receive recommended surveillance breast imaging longer-term," said study co-author Jessica R. Schumacher, PhD, an associate scientist at WiSOR. "The bulk of the disparity seems to occur in that first year of follow up, so it's really important to think about what we might be able to do in that timeframe to make sure women get guideline-recommended breast imaging."

In looking at the use of both MRI and mammography, the researchers found that receipt of mammography was not influenced by where a woman received her care, but MRI was.

"This finding shows that the problem is probably at the patient population level, as opposed to what we often see, which is that there is great variation in utilization of care across hospitals," Dr. Greenberg said. "MRI is a discretionary modality and not currently recommended in guidelines for routine surveillance following breast cancer treatment, but helpful and appropriate in certain patients. Therefore, it's much more vulnerable to local practice patterns, whereas mammogram is something we all know is effective and, in general, the likelihood of getting it doesn't matter where you receive your care."

Understanding why cancer survivors aren't receiving surveillance breast imaging and the consequences of this underutilization should be a high priority, the researchers note.

"We need to recognize the fact that, right now we are putting out more and more guidelines to help standardize care and to ensure patients get high quality care, but the guidelines that are already out there have been available for a long time. So I think it's important for health care practitioners to realize that it's not enough to just put information out there. Instead, we have to be more thoughtful about how we implement what we recommend into the actual care process," Dr. Greenberg said.  

Other study participants include Taiwo Adesoye, MD, MPH; Heather B. Neuman, MD, FACS; Stephen B. Edge, MD, FACS; Daniel P. McKellar, MD, FACS; David P. Winchester, MD, FACS; and Amanda B. Francescatti, MS.

"FACS" designates that a surgeon is Fellow of the American College of Surgeons.

Note: The data in this press release was updated from the published abstract and presented by Taiwo Adesoye, MD, MPH, during a Scientific Forum session at the 2016 Clinical Congress.  

Acknowledgement  Research reported in this press release was fully funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (CE-1304-6543). This publication was further made possible by CTSA Grant Numbers UL1 TR000135 and KL2TR000136-09 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH); the National Cancer Institute (NCI) of the NIH under award numbers U10CA031946, U10CA033601, U10CA180821, and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA076001 (to the American College of Surgeons Oncology Group), and U10CA025224 (to the North Central Cancer Oncology Group).

Disclaimer The research presented in this press release is solely the responsibility of the author(s) and does not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. The data used in the study are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator.

About the American College of Surgeons The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 80,000 members and is the largest organization of surgeons in the world. For more information, visit


To view the original version on PR Newswire, visit:

SOURCE American College of Surgeons



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
EpiCast Report: Acute Coronary Syndrome - Epidemio...
A Decade of Flat Funding Could Imperil Progress of...